News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
376,621 Results
Type
Article (23373)
Company Profile (120)
Press Release (353122)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (114533)
Career Advice (961)
Deals (20553)
Drug Delivery (80)
Drug Development (51042)
Employer Resources (95)
FDA (8829)
Job Trends (8496)
News (199255)
Policy (18496)
Tag
Academia (1342)
Academic (1)
Accelerated approval (7)
Adcomms (9)
Allergies (66)
Alliances (30231)
ALS (74)
Alzheimer's disease (756)
Antibody-drug conjugate (ADC) (75)
Approvals (8900)
Artificial intelligence (189)
Autoimmune disease (17)
Automation (10)
Bankruptcy (182)
Best Places to Work (6335)
BIOSECURE Act (11)
Biosimilars (91)
Biotechnology (50)
Bladder cancer (40)
Brain cancer (26)
Breast cancer (188)
Cancer (1447)
Cardiovascular disease (169)
Career advice (823)
Career pathing (21)
CAR-T (81)
CDC (19)
Cell therapy (219)
Cervical cancer (13)
Clinical research (43341)
Collaboration (610)
Company closure (1)
Compensation (253)
Complete response letters (22)
COVID-19 (1547)
CRISPR (40)
C-suite (265)
Cystic fibrosis (61)
Data (1804)
Denatured (21)
Depression (39)
Diabetes (194)
Diagnostics (2605)
Digital health (5)
Diversity (5)
Diversity, equity & inclusion (30)
Drug discovery (93)
Drug pricing (106)
Drug shortages (25)
Duchenne muscular dystrophy (89)
Earnings (41710)
Editorial (30)
Employer branding (8)
Employer resources (87)
Events (52463)
Executive appointments (588)
FDA (9895)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (2)
Frontotemporal dementia (3)
Funding (489)
Gene editing (69)
Generative AI (12)
Gene therapy (208)
GLP-1 (559)
Government (2184)
Grass and pollen (5)
Guidances (180)
Healthcare (7915)
HIV (28)
Huntington's disease (12)
IgA nephropathy (29)
Immunology and inflammation (83)
Immuno-oncology (3)
Indications (30)
Infectious disease (1637)
Inflammatory bowel disease (100)
Inflation Reduction Act (8)
Influenza (35)
Intellectual property (79)
Interviews (147)
IPO (8166)
IRA (40)
Job creations (2421)
Job search strategy (728)
Kidney cancer (8)
Labor market (33)
Layoffs (263)
Leadership (14)
Legal (4399)
Liver cancer (38)
Longevity (7)
Lung cancer (184)
Lymphoma (120)
Machine learning (7)
Management (34)
Manufacturing (293)
MASH (79)
Medical device (4090)
Medtech (4097)
Mergers & acquisitions (12797)
Metabolic disorders (533)
Multiple sclerosis (68)
NASH (19)
Neurodegenerative disease (65)
Neuropsychiatric disorders (18)
Neuroscience (1184)
NextGen: Class of 2025 (3118)
Non-profit (1987)
Now hiring (15)
Obesity (269)
Opinion (158)
Ovarian cancer (51)
Pain (95)
Pancreatic cancer (53)
Parkinson's disease (98)
Partnered (14)
Patents (179)
Patient recruitment (106)
Peanut (26)
People (38006)
Pharmaceutical (68)
Pharmacy benefit managers (16)
Phase I (11282)
Phase II (18726)
Phase III (16270)
Pipeline (1211)
Policy (154)
Postmarket research (1819)
Preclinical (4532)
Press Release (48)
Prostate cancer (92)
Psychedelics (23)
Radiopharmaceuticals (153)
Rare diseases (309)
Real estate (3395)
Recruiting (34)
Regulatory (13538)
Reports (22)
Research institute (1283)
Resumes & cover letters (123)
Rett syndrome (3)
RNA editing (5)
RSV (28)
Schizophrenia (63)
Series A (94)
Series B (57)
Service/supplier (5)
Sickle cell disease (46)
Special edition (9)
Spinal muscular atrophy (106)
Sponsored (11)
Startups (2257)
State (2)
Stomach cancer (6)
Supply chain (47)
Tariffs (58)
The Weekly (42)
Vaccines (468)
Venture capital (33)
Weight loss (175)
Women's health (22)
Worklife (9)
Date
Today (39)
Last 7 days (222)
Last 30 days (1192)
Last 365 days (15578)
2025 (10268)
2024 (17695)
2023 (20082)
2022 (27230)
2021 (29114)
2020 (27971)
2019 (24070)
2018 (18624)
2017 (19167)
2016 (18476)
2015 (21949)
2014 (16755)
2013 (13797)
2012 (14962)
2011 (15671)
2010 (14042)
Location
Africa (464)
Alabama (22)
Alaska (4)
Arizona (97)
Arkansas (4)
Asia (26905)
Australia (4043)
California (3491)
Canada (1434)
China (486)
Colorado (136)
Connecticut (138)
Delaware (119)
Europe (58085)
Florida (619)
Georgia (129)
Hawaii (1)
Idaho (24)
Illinois (377)
India (29)
Indiana (230)
Iowa (2)
Japan (183)
Kansas (73)
Kentucky (21)
Louisiana (10)
Maine (13)
Maryland (536)
Massachusetts (2761)
Michigan (69)
Minnesota (211)
Mississippi (1)
Missouri (47)
Montana (11)
Nebraska (11)
Nevada (36)
New Hampshire (14)
New Jersey (1338)
New Mexico (14)
New York (1085)
North Carolina (617)
North Dakota (2)
Northern California (1510)
Ohio (106)
Oklahoma (6)
Oregon (19)
Pennsylvania (842)
Puerto Rico (9)
Rhode Island (14)
South America (711)
South Carolina (13)
Southern California (1439)
Tennessee (56)
Texas (499)
United States (13985)
Utah (75)
Virginia (140)
Washington D.C. (45)
Washington State (308)
West Virginia (1)
Wisconsin (33)
376,621 Results for "simcere pharmaceutical group".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Antibody-drug conjugate (ADC)
NextCure Joins China-ADC Gold Rush with $745M Simcere Deal
The deal gets NextCure the rights to Simcere’s novel ADC for solid tumors outside of China.
June 16, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement
June 23, 2025
·
4 min read
Press Releases
Hengdian Group’s Apeloa Pharmaceutical uses Flow Chemistry for sustainable manufacturing
August 27, 2025
·
3 min read
Policy
Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA
On June 25, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group, announced that Enlituo®, a new generation anti-epidermal growth factor receptor antibody drug developed in collaboration with Mabpharm Limited, has recently received approval from the China National Medical Administration for marketing.
June 26, 2024
·
4 min read
Press Releases
Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China
July 10, 2025
·
7 min read
Press Releases
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
June 17, 2025
·
6 min read
Genetown
Simcere Pharmaceutical Group Announces Sponsored Research Agreement with Boston-based Mass General Brigham
Simcere Pharmaceutical Group Limited announced a Sponsored Research Agreement with Mass General Brigham.
June 12, 2023
·
5 min read
Press Releases
Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma
June 19, 2025
·
3 min read
Press Releases
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
July 30, 2025
·
7 min read
Legal
Medical Groups Sue RFK Jr. Over ‘Baseless and Uninformed’ Changes to COVID-19 Vaccine Policy
Societies, including the American Academy of Pediatrics, allege that Kennedy’s directive to remove COVID-19 from vaccination guidelines for healthy pregnant women and healthy children puts these vulnerable groups at risk of serious illness.
July 8, 2025
·
2 min read
·
Tristan Manalac
1 of 37,663
Next
